As large pharma companies increasingly turn to China to fill their pipelines, what long-term affect will it have on their strategy and operations? Pfizer's Andrew Baum shares the large drugmaker perspective on acquisitions, R&D, and how the industry could change in the years to come.Live from Endpoints’ China Biotech Debate: Boston on August 6, 2026.
Podden och tillhörande omslagsbild på den här sidan tillhör
Endpoints News. Innehållet i podden är skapat av Endpoints News och inte av,
eller tillsammans med, Poddtoppen.
